Patients typically take medications such as Zytiga for as long as they are effective for or as long as they can tolerate them.
The median amount of time patients with metastatic prostate cancer remained on Zytiga ranged from 8 to 24 months, according to the results from clinical trials used to gain Food and Drug Administration (FDA) approval for Zytiga in the US.